Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

Alex Sticchi provides his take on the results of the OPINION trial presented by Yang Wang at the ESC Congress 2025 in Madrid.

Paris, France 17 May 2022 – On the 19th of May the Andreas Grüntzig Ethica Award, the highest honour in the interventional cardiology community, will be awarded at EuroPCR 2022 to the Nurses and Allied Professionals community in recognition of the essential role they play in...

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Kalaivani Mahadevan and Fizzah Choudry provide their take on DAPT-SHOCK-MI presented by Zuzana Motovska at ESC Congress 2025 in Madrid.

Mirvat Alasnag provides her take on the TEER Shock study which was presented at TCT 2022 by Mohamad A. Alkhouli.

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.